Prospective Analysis of Central Nervous System Infection Risks in Varicella-Zoster Virus Reactivation Cases: A Single-Center Prospective Study of 1030 Cases

29 December 2024 : Clinical Research

Jun Wang^{ABEG 1*}, Yanrong Yuan^{BEF 1}, Huili Liu^{BCF 1}, Yan Zhang^{EF 1}, Yongxing Yan^{ACDG 1}

DOI: 10.12659/MSM.945835

Med Sci Monit 2024; 30:e945835

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 5 Multivariate logistic regression analysis of risk factors for concomitant CNS infection in patients with acute HZ.

	Variables	β	Wald	P	Exp.	95% CI
	Interval from onset to treatment	0.175	5.702	0.017	1.191	1.032–1.375
	Herpes site	−0.651	5.644	0.018	0.522	0.305–0.892
	Age	−0.023	3.617	0.057	0.977	0.954–1.001
	Cl−	−0.042	0.744	0.388	0.959	0.873–1.054
	C-reactive protein	0.042	6.912	0.009	1.043	1.011–1.076
	Glutamyltranspeptidase	0.002	0.122	0.727	1.002	0.992–1.011
	Albumin	−0.145	5.793	0.016	0.865	0.769–0.973
	Interval from onset to treatment	0.172	5.516	0.019	0.842	0.730–0.972
	Herpes site	−0.655	5.704	0.017	1.925	1.125–3.295
	Age	−0.025	4.036	0.055	1.025	1.001–1.051
	Cl−	−0.036	0.543	0.461	1.036	0.942–1.140
	C-reactive protein	0.043	7.299	0.007	0.958	0.928–0.988
	Glutamyltranspeptidase	0.002	0.127	0.722	0.998	0.989–1.008
	Albumin	−0.135	5.179	0.023	1.145	1.019–1.286
Model 1 has not been corrected. Model 2 corrected for potential confounding variables such as sex, concomitant tumor, type 2 diabetes, immunological diseases, and immunosuppressant use.

Back to the Article